Primary IgA Nephropathy: New Insights Into Pathogenesis

Seminars in Nephrology

Volumn 31, Issue 4, 2011, Pages 349-360

  Barratt, Jonathan ^a   Feehally, John ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Glomerulonephritis; IgA nephropathy; Immune complexes

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; AUTOANTIBODY; CD36 ANTIGEN; CD71 ANTIGEN; FC RECEPTOR; GLYCOSYLTRANSFERASE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN D; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; MEGALIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEPHRIN; OSTEOGENIC PROTEIN 1; ROSIGLITAZONE; THROMBOCYTE ACTIVATING FACTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL ACTIVATION; CELL DAMAGE; CELL PROLIFERATION; DOWN REGULATION; ENDOCYTOSIS; EPITHELIUM CELL; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION; HEREDITY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN AGGREGATE; INTERSTITIAL NEPHRITIS; KIDNEY PROXIMAL TUBULE; MESANGIUM CELL; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD; GALACTOSE; GLOMERULONEPHRITIS, IGA; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN A; KIDNEY TUBULES; MESANGIAL CELLS; PODOCYTES; RECEPTORS, FC; TOLL-LIKE RECEPTORS;

EID: 79961237330     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2011.06.006     Document Type: Article

References (94)

1. Berger J., Hinglais N. Les depots intercapillaries d'IgA-IgG. Journal d Urologie et de Nephrologie 1968, 74:694-695.
2. Suzuki K., Honda K., Tanabe K., et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003, 63:2286-2294.
3. Waldherr R., Rambausek M., Duncker W.D., et al. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 1989, 4:943-946.
4. Suzuki H., Fan R., Zhang Z., et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009, 119:1668-1677.
5. Lin X., Ding J., Zhu L., et al. Aberrant galactosylation of IgA1 is involved in the genetic susceptibility of Chinese patients with IgA nephropathy. Nephrol Dial Transplant 2009, 24:3372-3375.
6. Hastings M.C., Moldoveanu Z., Julian B.A., et al. Galactose-deficient IgA1 in african americans with IgA nephropathy: serum levels and heritability. Clin J Am Soc Nephrol 2010, 5:2069-2074.
7. Gharavi A.G., Moldoveanu Z., Wyatt R.J., et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 2008, 19:1008-1014.
8. Cattran D.C., Coppo R., Cook H.T., et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009, 76:534-545.
9. Tarelli E., Smith A.C., Hendry B.M., et al. Human serum IgA1 is substituted with up to six O-glycans as shown by matrix assisted laser desorption ionisation time-of-flight mass spectrometry. Carbohydr Res 2004, 339:2329-2335.
10. Suzuki H., Moldoveanu Z., Hall S., et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 2008, 118:629-639.
11. Moldoveanu Z., Wyatt R.J., Lee J.Y., et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 2007.
12. Allen A.C., Bailey E.M., Brenchley P.E., et al. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int 2001, 60:969-973.
13. Renfrow M.B., Mackay C.L., Chalmers M.J., et al. Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: implications for IgA nephropathy. Anal Bioanal Chem 2007, 389:1397-1407.
14. Hiki Y., Tanaka A., Kokubo T., et al. Analyses of IgA1 hinge glycopeptides in IgA nephropathy by matrix- assisted laser desorption/ionization time-of-flight mass spectrometry. J Am Soc Nephrol 1998, 9:577-582.
15. Royle L., Roos A., Harvey D.J., et al. Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. J Biol Chem 2003, 278:20140-20153.
16. Smith A.C., Molyneux K., Feehally J., et al. O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. J Am Soc Nephrol 2006, 17:3520-3528.
17. Smith A.C., de Wolff J.F., Molyneux K., et al. O-glycosylation of serum IgD in IgA nephropathy. J Am Soc Nephrol 2006, 17:1192-1199.
18. Yamada K., Kobayashi N., Ikeda T., et al. Down-regulation of core 1 β1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant 2010.
19. Kobayashi I., Nogaki F., Kusano H., et al. Interleukin-12 alters the physicochemical characteristics of serum and glomerular IgA and modifies glycosylation in a ddY mouse strain having high IgA levels. Nephrol Dial Transplant 2002, 17:2108-2116.
20. Chintalacharuvu S.R., Emancipator S.N. The glycosylation of IgA produced by murine B cells is altered by Th2 cytokines. J Immunol 1997, 159:2327-2333.
21. Rott L.S., Briskin M.J., Andrew D.P., et al. A fundamental subdivision of circulating lymphocytes defined by adhesion to mucosal addressin cell adhesion molecule-1. Comparison with vascular cell adhesion molecule-1 and correlation with beta 7 integrins and memory differentiation. J Immunol 1996, 156:3727-3736.
22. Schweighoffer T., Tanaka Y., Tidswell M., et al. Selective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with Hallmarks of gut-trophism. J Immunol 1993, 151:717-729.
23. Barratt J., Bailey E.M., Buck K.S., et al. Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy. Am J Kidney Dis 1999, 33:1049-1057.
24. Novak J., Julian B.A., Tomana M., et al. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol 2008, 28:78-87.
25. Harper S.J., Pringle J.H., Wicks A.C., et al. Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy. Kidney International 1994, 45:836-844.
26. Westberg N.G., Baklien K., Schmekel B., et al. Quantitation of immunoglobulin-producing cells in small intestinal mucosa of patients with IgA nephropathy. Clin Immunol Immunopathol 1983, 26:442-445.
27. de Fijter J.W., Eijgenraam J.W., Braam C.A., et al. Deficient IgA1 immune response to nasal cholera toxin subunit B in primary IgA nephropathy. Kidney Int 1996, 50:952-961.
28. Roodnat J.I., de Fijter J.W., van Kooten C., et al. Decreased IgA1 response after primary oral immunization with live typhoid vaccine in primary IgA nephropathy. Nephrol Dial Transplant 1999, 14:353-359.
29. Harper S.J., Allen A.C., Pringle J.H., et al. Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA. J Clin Pathol 1996, 49:38-42.
30. van den Wall Bake A.W., Daha M.R., Haaijman J.J., et al. Elevated production of polymeric and monomeric IgA1 by the bone marrow in IgA nephropathy. Kidney International 1989, 35:1400-1404.
31. Rostoker G., Petit-Phar M., Delprato S., et al. Mucosal immunity in primary glomerulonephritis: II. Study of the serum IgA subclass repertoire to food and airborne antigens. Nephron 1991, 59:561-566.
32. Gharavi A.G., Yan Y., Scolari F., et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 2000, 26:354-357.
33. Feehally J., Farrall M., Boland A., et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol 2010, 21:1791-1797.
34. Paterson A.D., Liu X.Q., Wang K., et al. Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J Am Soc Nephrol 2007, 18:2408-2415.
35. Bisceglia L., Cerullo G., Forabosco P., et al. Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. Am J Hum Genet 2006, 79:1130-1134.
36. Li G.S., Zhang H., Lv J.C., et al. Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. Kidney Int 2007, 71:448-453.
37. Li G.S., Zhu L., Zhang H., et al. Variants of the ST6GALNAC2 promoter influence transcriptional activity and contribute to genetic susceptibility to IgA nephropathy. Hum Mutat 2007.
38. Malycha F., Eggermann T., Hristov M., et al. No evidence for a role of cosmc-chaperone mutations in European IgA nephropathy patients. Nephrol Dial Transplant 2009, 24:321-324.
39. Qin W., Zhong X., Fan J.M., et al. External suppression causes the low expression of the Cosmc gene in IgA nephropathy. Nephrol Dial Transplant 2008, 23:1608-1614.
40. Qin W., Zhou Q., Yang L.C., et al. Peripheral B lymphocyte beta1,3-galactosyltransferase and chaperone expression in immunoglobulin A nephropathy. J Intern Med 2005, 258:467-477.
41. Ding J.X., Xu L.X., Zhu L., et al. Activity of alpha2,6-sialyltransferase and its gene expression in peripheral B lymphocytes in patients with IgA nephropathy. Scand J Immunol 2009, 69:174-180.
42. Oortwijn B.D., van der Boog P.J., Roos A., et al. A pathogenic role for secretory IgA in IgA nephropathy. Kidney Int 2006, 69:1131-1138.
43. Kokubo T., Hiki Y., Iwase H., et al. Evidence for involvement of IgA1 hinge glycopeptide in the IgA1-IgA1 interaction in IgA nephropathy. J Am Soc Nephrol 1997, 8:915-919.
44. Kokubo T., Hiki Y., Iwase H., et al. Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol 1998, 9:2048-2054.
45. Tomana M., Matousovic K., Julian B.A., et al. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 1997, 52:509-516.
46. Tomana M., Novak J., Julian B.A., et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 1999, 104:73-81.
47. Novak J., Tomana M., Matousovic K., et al. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int 2005, 67:504-513.
48. Monteiro R.C., Van De Winkel J.G. IgA Fc receptors. Annu Rev Immunol 2003, 21:177-204.
49. Launay P., Grossetete B., Arcos-Fajardo M., et al. Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice. J Exp Med 2000, 191:1999-2009.
50. Vuong M.T., Hahn-Zoric M., Lundberg S., et al. Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy. Kidney Int 2010.
51. Van Der Boog P.J., De Fijter J.W., Van Kooten C., et al. Complexes of IgA with FcalphaRI/CD89 are not specific for primary IgA nephropathy. Kidney Int 2003, 63:514-521.
52. Akira S. Mammalian Toll-like receptors. Curr Opin Immunol 2003, 15:5-11.
53. Peng S.L. Signaling in B cells via Toll-like receptors. Curr Opin Immunol 2005, 17:230-236.
54. Ashkar A.A., Rosenthal K.L. Toll-like receptor 9, CpG DNA and innate immunity. Curr Mol Med 2002, 2:545-546.
55. Blaas S.H., Stieber-Gunckel M., Falk W., et al. CpG-oligodeoxynucleotides stimulate immunoglobulin A secretion in intestinal mucosal B cells. Clin Exp Immunol 2009, 155:534-540.
56. Cognasse F., Acquart S., Beniguel L., et al. Differential production of immunoglobulin classes and subclasses by mucosal-type human B-lymphocytes exposed in vitro to CpG oligodeoxynucleotides. Clin Chem Lab Med 2005, 43:22-31.
57. Suzuki H., Suzuki Y., Narita I., et al. Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol 2008, 19:2384-2395.
58. Chuang T., Ulevitch R.J. Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells. Biochim Biophys Acta 2001, 1518:157-161.
59. Kormann M.S., Depner M., Hartl D., et al. Toll-like receptor heterodimer variants protect from childhood asthma. J Allergy Clin Immunol 2008, 122:86-92. 92 e81-88.
60. Mailaparambil B., Krueger M., Heinze J., et al. Polymorphisms of toll like receptors in the genetics of severe RSV associated diseases. Dis Markers 2008, 25:59-65.
61. Park H.J., Hahn W.H., Suh J.S., et al. Association between toll-like receptor 10 (TLR10) gene polymorphisms and childhood IgA nephropathy. Eur J Pediatr 2010.
62. O'Neill L.A. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008, 226:10-18.
63. Coppo R., Camilla R., Amore A., et al. Toll-like receptor 4 expression is increased in circulating mononuclear cells of patients with immunoglobulin A nephropathy. Clin Exp Immunol 2010, 159:73-81.
64. Cox S.N., Sallustio F., Serino G., et al. Altered modulation of WNT-beta-catenin and PI3K/Akt pathways in IgA nephropathy. Kidney Int 2010, 78:396-407.
65. Coppo R., Amore A., Peruzzi L., et al. Innate immunity and IgA nephropathy. J Nephrol 2010, 23:626-632.
66. Amore A., Cirina P., Conti G., et al. Glycosylation of circulating iga in patients with iga nephropathy modulates proliferation and apoptosis of mesangial cells. J Am Soc Nephrol 2001, 12:1862-1871.
67. Amore A., Conti G., Cirina P., et al. Aberrantly glycosylated IgA molecules downregulate the synthesis and secretion of vascular endothelial growth factor in human mesangial cells. Am J Kidney Dis 2000, 36:1242-1252.
68. Novak J., Vu H.L., Novak L., et al. Interactions of human mesangial cells with IgA and IgA-containing immune complexes. Kidney Int 2002, 62:465-475.
69. Moura I.C., Arcos-Fajardo M., Sadaka C., et al. Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol 2004, 15:622-634.
70. Leung J.C., Tang S.C., Chan L.Y., et al. Polymeric IgA increases the synthesis of macrophage migration inhibitory factor by human mesangial cells in IgA nephropathy. Nephrol Dial Transplant 2003, 18:36-45.
71. Lai K.N., Tang S.C., Guh J.Y., et al. Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the renin-angiotensin system. J Am Soc Nephrol 2003, 14:3127-3137.
72. Chan W.L., Leung J.C., Chan L.Y., et al. BMP-7 protects mesangial cells from injury by polymeric IgA. Kidney Int 2008, 74:1026-1039.
73. Gould S.E., Day M., Jones S.S., et al. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int 2002, 61:51-60.
74. Wang S., Hirschberg R. BMP7 antagonizes TGF-beta -dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol 2003, 284:F1006-F1013.
75. Wang S.N., Lapage J., Hirschberg R. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 2001, 12:2392-2399.
76. Klahr S., Morrissey J. Obstructive nephropathy and renal fibrosis: The role of bone morphogenic protein-7 and hepatocyte growth factor. Kidney Int 2003, (Suppl):S105-S112.
77. Lemley K.V., Lafayette R.A., Safai M., et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002, 61:1475-1485.
78. Hara M., Yanagihara T., Kihara I. Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schonlein-Henoch purpura nephritis. Clin J Am Soc Nephrol 2007, 2:231-238.
79. Gagliardini E., Benigni A., Tomasoni S., et al. Targeted downregulation of extracellular nephrin in human IgA nephropathy. Am J Nephrol 2003, 23:277-286.
80. Doublier S., Ruotsalainen V., Salvidio G., et al. Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol 2001, 158:1723-1731.
81. Lai K.N., Leung J.C., Chan L.Y., et al. Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol Dial Transplant 2009, 24:62-72.
82. Tian J., Wang H.P., Mao Y.Y., et al. Reduced glomerular epithelial protein 1 expression and podocyte injury in immunoglobulin A nephropathy. J Int Med Res 2007, 35:338-345.
83. Lai K.N., Leung J.C., Chan L.Y., et al. Activation of podocytes by mesangial-derived TNF-alpha: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol 2008, 294:F945-F955.
84. Wang C., Ye Z., Peng H., et al. Effect of aggregated immunoglobulin A1 from immunoglobulin A nephropathy patients on nephrin expression in podocytes. Nephrology (Carlton) 2008.
85. Matousovic K., Novak J., Yanagihara T., et al. IgA-containing immune complexes in the urine of IgA nephropathy patients. Nephrol Dial Transplant 2006, 21:2478-2484.
86. Wang C., Liu X., Ye Z., et al. Mesangial medium with IgA1 from IgA nephropathy inhibits nephrin expression in mouse podocytes. Eur J Clin Invest 2009, 39:561-567.
87. Baines R.J., Brunskill N.J. The molecular interactions between filtered proteins and proximal tubular cells in proteinuria. Nephron Exp Nephrol 2008, 110:e67-e71.
88. Chan L.Y., Leung J.C., Tsang A.W., et al. Activation of tubular epithelial cells by mesangial-derived TNF-alpha: glomerulotubular communication in IgA nephropathy. Kidney Int 2005, 67:602-612.
89. Kurita N., Honda S., Usui K., et al. Identification of the Fcalpha/muR isoform specifically expressed in the kidney tubules. Mol Immunol 2009, 46:749-753.
90. Motoyoshi Y., Matsusaka T., Saito A., et al. Megalin contributes to the early injury of proximal tubule cells during nonselective proteinuria. Kidney Int 2008, 74:1262-1269.
91. Chan L.Y., Leung J.C., Tang S.C., et al. Tubular expression of angiotensin II receptors and their regulation in IgA nephropathy. J Am Soc Nephrol 2005, 16:2306-2317.
92. Xiao J., Leung J.C., Chan L.Y., et al. Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy. Nephrol Dial Transplant 2009.
93. Xiao J., Leung J.C., Chan L.Y., et al. Crosstalk between peroxisome proliferator-activated receptor-gamma and angiotensin II in renal tubular epithelial cells in IgA nephropathy. Clin Immunol 2009, 132:266-276.
94. Sarafidis P.A., Bakris G.L. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 2006, 70:1223-1233.